J.P. Morgan analyst Jessica Fye has maintained their bullish stance on BMRN stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jessica Fye’s rating is based on BioMarin Pharmaceutical’s strong financial performance in the second quarter, where the company reported higher-than-expected revenues driven by its enzyme business. The company also increased its 2025 non-GAAP EPS guidance, excluding Inozyme, due to slightly higher revenue projections and improved profitability, which suggests a positive outlook for future earnings.
Furthermore, BioMarin’s stock is considered undervalued, with a durable base business and potential for significant operating margin expansion in the coming years. The market’s current expectations for the medium to long-term prospects of Voxzogo are seen as overly pessimistic, providing an opportunity for growth. Additionally, the ongoing development of new products, such as the long-acting CNP product BMN 333, and strategic initiatives, including cost transformation, contribute to the positive assessment of the company’s future potential.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $96.00 price target.